Base de dados : MEDLINE
Pesquisa : B04.280.210.600.550 [Categoria DeCS]
Referências encontradas : 376 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 38 ir para página                         

  1 / 376 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28768866
[Au] Autor:Liu J; Cattadori IM; Sim DG; Eden JS; Holmes EC; Read AF; Kerr PJ
[Ad] Endereço:CSIRO Health and Biosecurity, Black Mountain Laboratories, Acton, ACT, Australia.
[Ti] Título:Reverse Engineering Field Isolates of Myxoma Virus Demonstrates that Some Gene Disruptions or Losses of Function Do Not Explain Virulence Changes Observed in the Field.
[So] Source:J Virol;91(20), 2017 Oct 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The coevolution of myxoma virus (MYXV) and wild European rabbits in Australia and Europe is a paradigm for the evolution of a pathogen in a new host species. Genomic analyses have identified the mutations that have characterized this evolutionary process, but defining causal mutations in the pathways from virulence to attenuation and back to virulence has not been possible. Using reverse genetics, we examined the roles of six selected mutations found in Australian field isolates of MYXV that fall in known or potential virulence genes. Several of these mutations occurred in genes previously identified as virulence genes in whole-gene knockout studies. Strikingly, no single or double mutation among the mutations tested had an appreciable impact on virulence. This suggests either that virulence evolution was defined by amino acid changes other than those analyzed here or that combinations of multiple mutations, possibly involving epistatic interactions or noncoding sequences, have been critical in the ongoing evolution of MYXV virulence. In sum, our results show that single-gene knockout studies of a progenitor virus can have little power to predict the impact of individual mutations seen in the field. The genetic determinants responsible for this canonical case of virulence evolution remain to be determined. The species jump of myxoma virus (MYXV) from the South American tapeti to the European rabbit populations of Australia and Europe is a canonical example of host-pathogen coevolution. Detailed molecular studies have identified multiple genes in MYXV that are critical for virulence, and genome sequencing has revealed the evolutionary history of MYXV in Australia and Europe. However, it has not been possible to categorically identify the key mutations responsible for the attenuation of or reversion to virulence during this evolutionary process. Here we use reverse genetics to examine the role of mutations in viruses isolated early and late in the Australian radiation of MYXV. Surprisingly, none of the candidate mutations that we identified as likely having roles in attenuation proved to be important for virulence. This indicates that considerable caution is warranted when interpreting the possible role of individual mutations during virulence evolution.
[Mh] Termos MeSH primário: Genoma Viral
Mutação
Myxoma virus/genética
Myxoma virus/patogenicidade
Genética Reversa
Fatores de Virulência/genética
[Mh] Termos MeSH secundário: Animais
Austrália
Evolução Molecular
Técnicas de Inativação de Genes
Genômica
Myxoma virus/classificação
Myxoma virus/isolamento & purificação
Filogenia
Coelhos
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Virulence Factors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE


  2 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28407327
[Au] Autor:Rahal A; Musher B
[Ad] Endereço:Division of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
[Ti] Título:Oncolytic viral therapy for pancreatic cancer.
[So] Source:J Surg Oncol;116(1):94-103, 2017 Jul.
[Is] ISSN:1096-9098
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Outcomes of pancreatic adenocarcinoma (PDA) remain dismal despite extensive clinical investigation. Combination chemotherapy provides modest improvements in survival above best supportive care, and immunotherapy has thus far not proven effective. Nevertheless, growing insight into antitumor immunity and the tumor microenvironment has inspired the discovery of novel agents targeting PDA. Oncolytic viruses represent an emerging class of immunotherapeutic agents that have undergone extensive preclinical investigation and warrant further investigation in well-designed clinical trials.
[Mh] Termos MeSH primário: Terapia Viral Oncolítica
Neoplasias Pancreáticas/terapia
[Mh] Termos MeSH secundário: Adenocarcinoma/imunologia
Adenocarcinoma/terapia
Adenoviridae
Animais
Ensaios Clínicos como Assunto
Seres Humanos
Vírus do Sarampo
Myxoma virus
Orthoreovirus de Mamíferos
Neoplasias Pancreáticas/imunologia
Parvovirus
Simplexvirus
Microambiente Tumoral
Vírus Vaccinia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1002/jso.24626


  3 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28253375
[Au] Autor:Kerr PJ; Cattadori IM; Rogers MB; Fitch A; Geber A; Liu J; Sim DG; Boag B; Eden JS; Ghedin E; Read AF; Holmes EC
[Ad] Endereço:Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia.
[Ti] Título:Genomic and phenotypic characterization of myxoma virus from Great Britain reveals multiple evolutionary pathways distinct from those in Australia.
[So] Source:PLoS Pathog;13(3):e1006252, 2017 Mar.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The co-evolution of myxoma virus (MYXV) and the European rabbit occurred independently in Australia and Europe from different progenitor viruses. Although this is the canonical study of the evolution of virulence, whether the genomic and phenotypic outcomes of MYXV evolution in Europe mirror those observed in Australia is unknown. We addressed this question using viruses isolated in the United Kingdom early in the MYXV epizootic (1954-1955) and between 2008-2013. The later UK viruses fell into three distinct lineages indicative of a long period of separation and independent evolution. Although rates of evolutionary change were almost identical to those previously described for MYXV in Australia and strongly clock-like, genome evolution in the UK and Australia showed little convergence. The phenotypes of eight UK viruses from three lineages were characterized in laboratory rabbits and compared to the progenitor (release) Lausanne strain. Inferred virulence ranged from highly virulent (grade 1) to highly attenuated (grade 5). Two broad disease types were seen: cutaneous nodular myxomatosis characterized by multiple raised secondary cutaneous lesions, or an amyxomatous phenotype with few or no secondary lesions. A novel clinical outcome was acute death with pulmonary oedema and haemorrhage, often associated with bacteria in many tissues but an absence of inflammatory cells. Notably, reading frame disruptions in genes defined as essential for virulence in the progenitor Lausanne strain were compatible with the acquisition of high virulence. Combined, these data support a model of ongoing host-pathogen co-evolution in which multiple genetic pathways can produce successful outcomes in the field that involve both different virulence grades and disease phenotypes, with alterations in tissue tropism and disease mechanisms.
[Mh] Termos MeSH primário: Evolução Molecular
Myxoma virus/genética
Myxoma virus/patogenicidade
Mixomatose Infecciosa/genética
Virulência/genética
[Mh] Termos MeSH secundário: Animais
Austrália
Genes Virais/genética
Genótipo
Fenótipo
Filogenia
Reação em Cadeia da Polimerase
Coelhos
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006252


  4 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28157624
[Au] Autor:Nounamo B; Li Y; O'Byrne P; Kearney AM; Khan A; Liu J
[Ad] Endereço:Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
[Ti] Título:An interaction domain in human SAMD9 is essential for myxoma virus host-range determinant M062 antagonism of host anti-viral function.
[So] Source:Virology;503:94-102, 2017 Mar.
[Is] ISSN:1096-0341
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In humans, deleterious mutations in the sterile α motif domain protein 9 (SAMD9) gene are associated with cancer, inflammation, weakening of the immune response, and developmental arrest. However, the biological function of SAMD9 and its sequence-structure relationships remain to be characterized. Previously, we found that an essential host range factor, M062 protein from myxoma virus (MYXV), antagonized the function of human SAMD9. In this study, we examine the interaction between M062 and human SAMD9 to identify regions that are critical to SAMD9 function. We also characterize the in vitro kinetics of the interaction. In an infection assay, exogenous expression of SAMD9 N-terminus leads to a potent inhibition of wild-type MYXV infection. We reason that this effect is due to the sequestration of viral M062 by the exogenously expressed N-terminal SAMD9 region. Our studies reveal the first molecular insight into viral M062-dependent mechanisms that suppress human SAMD9-associated antiviral function.
[Mh] Termos MeSH primário: Myxoma virus/metabolismo
Proteínas/antagonistas & inibidores
Proteínas Virais/metabolismo
[Mh] Termos MeSH secundário: Células A549
Animais
Linhagem Celular Tumoral
Células HEK293
Células HeLa
Especificidade de Hospedeiro
Seres Humanos
Camundongos
Myxoma virus/genética
Estrutura Terciária de Proteína
Proteínas/genética
Proteínas Virais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (M062 protein, myxoma virus); 0 (Proteins); 0 (SAMD9 protein, human); 0 (Viral Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170204
[St] Status:MEDLINE


  5 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28157174
[Au] Autor:Rahman MM; McFadden G
[Ad] Endereço:The Biodesign Institute, Center for Immunotherapy, Vaccines, and Virotherapy, Arizona State University, Tempe, AZ 85287-5401, USA. Masmudur.Rahman@asu.edu.
[Ti] Título:Myxoma Virus dsRNA Binding Protein M029  Inhibits the Type I IFN-Induced Antiviral State in a  Highly Species-Specific Fashion.
[So] Source:Viruses;9(2), 2017 Feb 02.
[Is] ISSN:1999-4915
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Myxoma virus (MYXV) is Leporipoxvirus that possesses a specific rabbit-restricted host tropism but exhibits a much broader  cellular host range in cultured cells. MYXV is able to efficiently  block all aspects of the type I interferon (IFN)-induced  antiviral  state  in rabbit cells, partially in  human  cells  and  very  poorly  in  mouse  cells.  The mechanism(s) of this species-specific inhibition of  type I IFN-induced antiviral state is not well understood. Here we demonstrate that MYXV encoded  protein  M029, a truncated relative of the vaccinia virus (VACV) E3 double-stranded RNA (dsRNA)  binding  protein  that  inhibits  protein  kinase  R (PKR),  can  also  antagonize the type I IFN-induced  antiviral state in a highly species-specific manner. In cells pre-treated with type I IFN prior to  infection,  MYXV  exploits  M029  to  overcome  the  induced  antiviral  state completely in rabbit cells,  partially  in  human  cells,  but  not at all in mouse cells. However, in cells pre-infected with MYXV,  IFN-induced  signaling  is fully  inhibited  even  in the  absence  of M029 in cells from all three species,  suggesting  that  other  MYXV  protein(s)  apart  from  M029  block  IFN  signaling  in  a  speciesindependent  manner.  We  also  show  that  the  antiviral  state  induced in rabbit, human or mouse cells  by  type  I IFN  can  inhibit M029-knockout MYXV even when PKR is genetically knocked-out, suggesting  that  M029  targets  other  host  proteins  for  this  antiviral state inhibition. Thus, the MYXV  dsRNA  binding  protein  M029  not  only  antagonizes  PKR  from  multiple  species  but  also blocks the  type I IFN antiviral state independently of PKR in a highly species-specific fashion.
[Mh] Termos MeSH primário: Interações Hospedeiro-Patógeno
Evasão da Resposta Imune
Interferon Tipo I/antagonistas & inibidores
Myxoma virus/patogenicidade
Proteínas de Ligação a RNA/metabolismo
Proteínas Virais/metabolismo
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Seres Humanos
Camundongos
Coelhos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interferon Type I); 0 (RNA-Binding Proteins); 0 (Viral Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170204
[St] Status:MEDLINE


  6 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27903800
[Au] Autor:Braun C; Thürmer A; Daniel R; Schultz AK; Bulla I; Schirrmeier H; Mayer D; Neubert A; Czerny CP
[Ad] Endereço:Department of Animal Sciences, Institute of Veterinary Medicine, Division of Microbiology and Animal Hygiene, Faculty of Agricultural Sciences, Georg August University Göttingen, Göttingen, Germany.
[Ti] Título:Genetic Variability of Myxoma Virus Genomes.
[So] Source:J Virol;91(4), 2017 Feb 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Myxomatosis is a recurrent problem on rabbit farms throughout Europe despite the success of vaccines. To identify gene variations of field and vaccine strains that may be responsible for changes in virulence, immunomodulation, and immunoprotection, the genomes of 6 myxoma virus (MYXV) strains were sequenced: German field isolates Munich-1, FLI-H, 2604, and 3207; vaccine strain MAV; and challenge strain ZA. The analyzed genomes ranged from 147.6 kb (strain MAV) to 161.8 kb (strain 3207). All sequences were affected by several mutations, covering 24 to 93 open reading frames (ORFs) and resulted in amino acid substitutions, insertions, or deletions. Only strains Munich-1 and MAV revealed the deletion of 10 ORFs (M007L to M015L) and 11 ORFs (M007L to M008.1L and M149R to M008.1R), respectively. Major differences were observed in the 27 immunomodulatory proteins encoded by MYXV. Compared to the reference strain Lausanne, strains FLI-H, 2604, 3207, and ZA showed the highest amino acid identity (>98.4%). In strains Munich-1 and MAV, deletion of 5 and 10 ORFs, respectively, was observed, encoding immunomodulatory proteins with ankyrin repeats or members of the family of serine protease inhibitors. Furthermore, putative immunodominant surface proteins with homology to vaccinia virus (VACV) were investigated in the sequenced strains. Only strain MAV revealed above-average frequencies of amino acid substitutions and frameshift mutations. Finally, we performed recombination analysis and found signs of recombination in vaccine strain MAV. Phylogenetic analysis showed a close relationship of strain MAV and the MSW strain of Californian MYXV. However, in a challenge model, strain MAV provided full protection against lethal challenges with strain ZA. IMPORTANCE: Myxoma virus (MYXV) is pathogenic for European rabbits and two North American species. Due to sophisticated strategies in immune evasion and oncolysis, MYXV is an important model virus for immunological and pathological research. In its natural hosts, MYXV causes a benign infection, whereas in European rabbits, it causes the lethal disease myxomatosis. Since the introduction of MYXV into Australia and Europe for the biological control of European rabbits in the 1950s, a coevolution of host and pathogen has started, selecting for attenuated virus strains and increased resistance in rabbits. Evolution of viruses is a continuous process and influences the protective potential of vaccines. In our analyses, we sequenced 6 MYXV field, challenge, and vaccine strains. We focused on genes encoding proteins involved in virulence, host range, immunomodulation, and envelope composition. Genes affected most by mutations play a role in immunomodulation. However, attenuation cannot be linked to individual mutations or gene disruptions.
[Mh] Termos MeSH primário: Variação Genética
Genoma Viral
Myxoma virus/genética
Infecções por Poxviridae/virologia
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Animais
Repetição de Anquirina
Apoptose
Linhagem Celular
Cercopithecus aethiops
Evolução Molecular
Genômica/métodos
Imunomodulação
Inflamação/imunologia
Inflamação/metabolismo
Inflamação/virologia
Leucócitos/imunologia
Leucócitos/metabolismo
Mutação
Myxoma virus/classificação
Myxoma virus/imunologia
Fases de Leitura Aberta
Filogenia
Infecções por Poxviridae/imunologia
Infecções por Poxviridae/prevenção & controle
Ligação Proteica
Mapeamento de Interação de Proteínas
Coelhos
Receptores Imunológicos
Proteínas Virais/genética
Proteínas Virais/imunologia
Proteínas Virais/metabolismo
Vacinas Virais/genética
Vacinas Virais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Receptors, Immunologic); 0 (Viral Proteins); 0 (Viral Vaccines)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161202
[St] Status:MEDLINE


  7 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27892861
[Au] Autor:Pacios-Palma I; Santoro S; Bertó-Moran A; Moreno S; Rouco C
[Ad] Endereço:Ethology and Biodiversity Conservation Department, Doñana Biological Station-CSIC, AméricoVespucio s/n, 41092 Seville, Spain. Electronic address: isa_pacios@ebd.csic.es.
[Ti] Título:Effects of myxoma virus and rabbit hemorrhagic disease virus on the physiological condition of wild European rabbits: Is blood biochemistry a useful monitoring tool?
[So] Source:Res Vet Sci;109:129-134, 2016 Dec.
[Is] ISSN:1532-2661
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Myxomatosis and rabbit hemorrhagic disease (RHD) are the major viral diseases that affect the wild European rabbit (Oryctolagus cuniculus). These diseases arrived in Europe within the last decades and have caused wild rabbit populations to decline dramatically. Both viruses are currently considered to be endemic in the Iberian Peninsula; periodic outbreaks that strongly impact wild populations regularly occur. Myxoma virus (MV) and rabbit hemorrhagic disease virus (RHDV) alter the physiology of infected rabbits, resulting in physical deterioration. Consequently, the persistence and viability of natural populations are affected. The main goal of our study was to determine if blood biochemistry is correlated with serostatus in wild European rabbits. We carried out seven live-trapping sessions in three wild rabbit populations over a two-year period. Blood samples were collected to measure anti-MV and anti-RHDV antibody concentrations and to measure biochemical parameters related to organ function, protein metabolism, and nutritional status. Overall, we found no significant relationships between rabbit serostatus and biochemistry. Our main result was that rabbits that were seropositive for both MV and RHDV had low gamma glutamyltransferase concentrations. Given the robustness of our analyses, the lack of significant relationships may indicate that the biochemical parameters measured are poor proxies for serostatus. Another explanation is that wild rabbits might be producing attenuated physiological responses to these viruses because the latter are now enzootic in the study area.
[Mh] Termos MeSH primário: Infecções por Caliciviridae/veterinária
Vírus da Doença Hemorrágica de Coelhos/fisiologia
Myxoma virus/fisiologia
Mixomatose Infecciosa/epidemiologia
Coelhos
[Mh] Termos MeSH secundário: Animais
Análise Química do Sangue/veterinária
Infecções por Caliciviridae/epidemiologia
Infecções por Caliciviridae/virologia
Feminino
Masculino
Mixomatose Infecciosa/virologia
Prevalência
Estudos Soroepidemiológicos
Espanha/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170221
[Lr] Data última revisão:
170221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE


  8 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27663647
[Au] Autor:Rouco C; Moreno S; Santoro S
[Ad] Endereço:Departamento de Zoología, Campus de Rabanales, Universidad de Córdoba, 14071 Córdoba, Spain; Ethology and Biodiversity Conservation Department, Doñana Biological Station-CSIC, Américo Vespucio S/N, 41092 Seville, Spain; Landcare Research, P.O. Box 1930, 9054 Dunedin, New Zealand. Electronic address: c.rouco@gmail.com.
[Ti] Título:A case of low success of blind vaccination campaigns against myxomatosis and rabbit haemorrhagic disease on survival of adult European wild rabbits.
[So] Source:Prev Vet Med;133:108-113, 2016 Oct 01.
[Is] ISSN:1873-1716
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Vaccination campaigns against myxomatosis and rabbit haemorrhagic disease (RHD) are commonly used in translocation programs conducted for the purpose of recovering wild European rabbit populations in Iberian Mediterranean ecosystems. In most cases rabbits are vaccinated 'blind' (i.e. without assessing their prior immunological status) for economic and logistic reasons. However, there is conflicting evidence on the effectiveness of such an approach. We tested whether blind vaccination against myxomatosis and rabbit haemorrhagic disease improved rabbit survival in a rabbit translocation program where wild rabbits were kept in semi-natural conditions in three enclosures. We conducted nine capture sessions over two years (2008-2010) and used the information collected to compare the survival of vaccinated (n=511) versus unvaccinated (n=161) adult wild rabbits using capture-mark-recapture analysis. Average monthly survival was no different for vaccinated versus unvaccinated individuals, both in the period between release and first capture (short-term) and after the first capture onward (long-term). Rabbit survival was lower in the short term than in the long term regardless of whether rabbits were vaccinated or not. Lower survival in the short-term could be due to the stress induced by the translocation process itself (e.g. handling stress). However, we did not find any overall effect of vaccination on survival which could be explained by two non-exclusive reasons. First, interference of the vaccine with the natural antibodies in the donor population. Due to donor populations have high density of rabbits with, likely, high prevalence of antibodies as a result of previous natural exposure to these diseases. Second, the lack of severe outbreaks during the study period. Based on our findings we argue that blind vaccination of adult rabbits in translocation programs may be often mostly ineffective and unnecessarily costly. In particular, since outbreaks are hard to predict and vaccination of rabbits with natural antibodies is ineffective, it is crucial to assess the immunological status of the donor population before translocating adult rabbits.
[Mh] Termos MeSH primário: Infecções por Caliciviridae/veterinária
Vírus da Doença Hemorrágica de Coelhos/imunologia
Myxoma virus/imunologia
Mixomatose Infecciosa/prevenção & controle
Vacinação/veterinária
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Animais Selvagens
Infecções por Caliciviridae/prevenção & controle
Feminino
Masculino
Mixomatose Infecciosa/virologia
Coelhos
Espanha
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160925
[St] Status:MEDLINE


  9 / 376 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27035991
[Au] Autor:Burgess HM; Mohr I
[Ad] Endereço:Department of Microbiology, New York University School of Medicine, New York, NY 10016;
[Ti] Título:Evolutionary clash between myxoma virus and rabbit PKR in Australia.
[So] Source:Proc Natl Acad Sci U S A;113(15):3912-4, 2016 Apr 12.
[Is] ISSN:1091-6490
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Evolução Biológica
Myxoma virus
[Mh] Termos MeSH secundário: Animais
Austrália
Coelhos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170412
[Lr] Data última revisão:
170412
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160402
[St] Status:MEDLINE
[do] DOI:10.1073/pnas.1602063113


  10 / 376 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27011200
[Au] Autor:Villa NY; Rahman MM; McFadden G; Cogle CR
[Ad] Endereço:Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA. nancy.villa@medicine.ufl.edu.
[Ti] Título:Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.
[So] Source:Viruses;8(3):85, 2016 Mar 22.
[Is] ISSN:1999-4915
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage mediated by donor lymphocytes. Despite immune suppression, GVHD is highly incident even after allo-HSCT using human leukocyte antigen (HLA)-matched donors. Therefore, alternative and more effective therapies are needed to prevent or control GVHD while preserving the beneficial graft-versus-cancer (GVC) effects against residual disease. Among novel therapeutics for GVHD, oncolytic viruses such as myxoma virus (MYXV) are receiving increased attention due to their dual role in controlling GVHD while preserving or augmenting GVC. This review focuses on the molecular basis of GVHD, as well as state-of-the-art advances in developing novel therapies to prevent or control GVHD while minimizing impact on GVC. Recent literature regarding conventional and the emerging therapies are summarized, with special emphasis on virotherapy to prevent GVHD. Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed.
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/prevenção & controle
Doença Enxerto-Hospedeiro/terapia
Terapia Viral Oncolítica/métodos
[Mh] Termos MeSH secundário: Animais
Avaliação Pré-Clínica de Medicamentos
Doença Enxerto-Hospedeiro/fisiopatologia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Seres Humanos
Myxoma virus/crescimento & desenvolvimento
Transplante Homólogo/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Em] Mês de entrada:1611
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160325
[St] Status:MEDLINE



página 1 de 38 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde